Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 14, 2015 at 3.05 p.m.Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets ActBiotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) (“Biotie” or the “Company”) has on December 12, 2015 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Versant Ventures III, LLC on behalf of itself and Versant Venture Capital III, L.P. as a result of the implementation of changes to the transparency directive in the Finnish Securities Market Act.According to the notification, the total number of Biotie shares owned directly or through financial instruments by Versant Ventures III, LLC and its funds was 8.02 per cent of Biotie’s total number of shares and voting rights on 26 November 2015. Biotie’s registered total number of shares and voting rights amounting to 1,086,940,271 has been used in the calculation of percentages for the announcement.Total positions of Versant Ventures III, LLC and its funds subject to the notification:Notified details of the resulting situation on the date on which the threshold was crossed or reached:A: Shares and voting rightsB: Financial instruments according to SMA 9:6aFor further information on the warrants, the notification refers to the stock exchange release issued by the Company on April 23, 2015.Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:According to the notification, Versant Ventures III, LLC is the sole general partner of (i) Versant Venture Capital III, L.P. and (ii) Versant Side Fund III, L.P. Neither Versant Ventures III, LLC nor any other entity under its control, other than (i) Versant Venture Capital III, L.P. and (ii) Versant Side Fund III, L.P., holds any shares or financial instruments in the Company.In Turku, December 14, 2015Biotie Therapies Corp.Timo Veromaa
President and CEOFor further information, please contact:Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: email@example.comDISTRIBUTION:NASDAQ OMX Helsinki Ltd